about
A tetraploid intermediate precedes aneuploid formation in yeasts exposed to fluconazoleA repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosisCandida albicans morphogenesis is not required for macrophage interleukin 1β production.The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis.Enhanced phagocytosis of Candida species mediated by opsonization with a recombinant human antibody single-chain variable fragmentEstrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo.Catching fire: Candida albicans, macrophages, and pyroptosis.Live Candida albicans suppresses production of reactive oxygen species in phagocytes.Antifungal activity of tamoxifen: in vitro and in vivo activities and mechanistic characterizationNitrite reductase NirS is required for type III secretion system expression and virulence in the human monocyte cell line THP-1 by Pseudomonas aeruginosa.Candida albicans triggers NLRP3-mediated pyroptosis in macrophages.Monocyte responses to Candida albicans are enhanced by antibody in cooperation with antibody-independent pathogen recognition.Role of the 14-3-3 protein in carbon metabolism of the pathogenic yeast Candida albicans.Systematic Complex Haploinsufficiency-Based Genetic Analysis of Candida albicans Transcription Factors: Tools and Applications to Virulence-Associated Phenotypes.Pacifier as a risk factor for acute otitis media.
P50
Q27315613-6D99053A-DB5F-420A-B2DC-407243B8DF1EQ34513852-85605B7C-27CC-4733-85DE-D33270959F31Q34523437-D44056E0-44E1-44F9-9419-781FECF13B6FQ34540684-36609F54-213A-47CB-A6B9-CA4D158D297CQ34946997-A2D0D4F6-79A2-4D51-A590-11D0031807A5Q35092521-CFE45A1E-C385-4C52-8BCF-7935EA9C184FQ35195507-C7AF4127-0360-4423-BE81-A41AD31B723AQ37032994-DC52686B-01AD-41C2-A97D-D21651CD6FF2Q37274621-663C117E-5305-43A9-8FB6-91F28AB745AEQ37355875-53EB20E8-0B96-42EA-9FF6-66FC5F98CCC8Q37545146-D7E67120-7BF1-4B79-A6D2-47F8E768C710Q40111677-F6A8BFB1-BD9A-45AF-8243-30E5479EB617Q44936986-6B293B0A-E73E-4D32-B935-02051128C95EQ52374553-431FAEC9-7BC3-48D1-AFEC-A3F8832F3017Q55035671-D7A84FFE-4F78-4450-B8EA-2089D851CB73
P50
description
researcher ORCID ID = 0000-0001-9994-1254
@en
wetenschapper
@nl
name
Melanie Wellington
@ast
Melanie Wellington
@en
Melanie Wellington
@es
Melanie Wellington
@nl
type
label
Melanie Wellington
@ast
Melanie Wellington
@en
Melanie Wellington
@es
Melanie Wellington
@nl
prefLabel
Melanie Wellington
@ast
Melanie Wellington
@en
Melanie Wellington
@es
Melanie Wellington
@nl
P1153
6701410647
P31
P496
0000-0001-9994-1254